REG - IQ-AI Limited - Second FDA Rare Pediatric Disease Designation

IQ-AIAnnouncement

20/05/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240520:nRST0655Pa&default-theme=true

RNS Number : 0655P  IQ-AI Limited  20 May 2024

May 20, 2024

IQ-AI Ltd

("IQ-AI" or the "Company")

 

Imaging Biometrics Announces Second U.S. FDA Rare Pediatric Disease
Designation Granted to GaM

 

For the Treatment of Pediatric-Type Diffuse High Grade Glioma ("HGG")

Further to the announcements made on 8 November 2023 and 10 May 2024, Imaging
Biometrics ("IB"), Elm Grove, WI, a wholly owned subsidiary of IQ-AI Ltd
(LSE:  IQAI), today announces that the U.S. Food and Drug Administration (the
"FDA") has granted Rare Pediatric Disease Designation ("RPDD") to IB-003 for
the treatment of pediatric-type diffuse HGG. IB-003 is the Company's lead drug
candidate, oral gallium maltolate ("GaM").

Recently, the FDA granted RPDD to GaM for the treatment of atypical teratoid
rhabdoid tumor ("ATRT").

Pediatric-type diffuse HGG, which now consists of four molecularly distinct
subtypes according to the 2021 World Health Organization Classification of the
Central Nervous System, fifth edition ("2021 WHO CNS5"), falls within this
population.  Prior to the WHO reclassification, these tumors were referred to
as pediatric glioblastoma. The four subtypes include diffuse midline glioma,
diffuse hemispheric glioma H3 G34-mutant, diffuse pediatric high-grade glioma
H3 wildtype and IDH wildtype, and infant-type hemispheric glioma.

Rare pediatric diseases are defined by the FDA as serious or life threatening
that affect less than 200,000 people under 18 years of age. Like ATRT,
pediatric-type diffuse HGG meets this criterion. These cancers have a poor
prognosis primarily due to the early dissemination of cancer cells through the
cerebrospinal fluid. Moreover, treating these tumors is especially difficult
due to their location and the challenges of surgically resecting tumor tissue.

This RPDD designation request also leveraged data obtained from the
pre-clinical study by Mona Al-Gizawiy, PhD in the laboratory of Kathleen
Schmainda, PhD at the Medical College of Wisconsin. As announced on 27 June
2023, the study showed growth inhibition and a survival benefit from treatment
with IB-003. Specifically, median overall survival for pediatric glioblastoma
was 21 days in the control group and 49 days in the treated group.

Having multiple RPDDs offers both strategic and financial advantages in
advancing treatment for rare pediatric diseases. Of these, priority review
vouchers ("PRV") are the most significant. Upon new drug application ("NDA")
approval by the FDA, a sponsor becomes eligible for a PRV. The PRV can then be
redeemed to obtain a priority review for another NDA, or they can be sold or
transferred to other companies.

 

"This second Rare Pediatric Disease Designation for IB-003 reflects our
commitment to address the needs of children affected by these conditions,"
said Trevor Brown, CEO of IQ-AI Ltd. "Building upon these designations, we are
exploring ways to accelerate and expand the application of IB-003."

 

--ENDS-

 

 

The Directors of the Company accept responsibility for the contents of this
announcement.

 

For further information, please contact:

 

 IQ-AI Ltd

 Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda

 Tel: 020 7469 0930
 Peterhouse Capital Limited (Financial Adviser and Broker)

 Lucy Williams/Heena Karani

 Tel: 020 7220 9797

 

 

 

About Imaging Biometrics® LLC:  IB is a wholly owned subsidiary of IQ-AI
Limited, (LON: IQAI), and focuses on delivering quantitative imaging platforms
and therapeutics that transform how clinicians diagnose and treat patients
more efficiently and effectively. For more information about Imaging
Biometrics, visit the company's website at www.imagingbiometrics.com
(http://www.imagingbiometrics.com/) . Follow IB on Twitter, @IQAI_IB.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRPPUMUAUPCUQU